We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




German-Israeli Center for Brain Research Dedicated in Recent Ceremony

By LabMedica International staff writers
Posted on 21 Jan 2013
A new center for collaborative brain research between German and Israeli scientists was dedicated in a ceremony held recently in Jerusalem.

The new center, called the Max Planck-Hebrew University Center for Sensory Processing of the Brain in Action, will be staffed by researchers from the Max Planck Institute of Neurobiology (Martinsried, Germany) and the Edmond and Lily Safra Center for Brain Sciences at the Hebrew University of Jerusalem (Israel).

The new center, which is to be housed at the Hebrew University of Jerusalem, will be funded at three million euros for its first five years. More...
It is one of only nine such international partnerships between the Max Planck Society and a foreign research institution and is the only one in the field of brain research.

Researchers from the two institutions will be studying both individual nerve cells as well as circuits of cells and analyzing how sensory perceptions are processed in the brain. These topics mesh well with the Hebrew University's interdisciplinary approach that includes neuroscientists, physicists, computer scientists, cognitive scientists, and others who focus on several broad areas of inquiry, including genes and neurons, neural networks learning and plasticity, cognitive neuroscience, computational neuroscience, and sensory and motor functions.

Special emphasis will be placed on recruiting young Israeli and German investigators through fellowships and joint research programs.

“The center raises our long-standing partnership in the field of neuroscience to a new level of quality. It offers the prospect of an entirely new dimension in the study of the brain in particular,” said Dr. Peter Gruss, the president of the Max Planck Society.

President of the Hebrew University of Jerusalem Dr. Menahem Ben-Sasson, said, “Cooperation with Germany in science and research is among the most important and fruitful of our international contacts, and makes it possible for us to be at the forefront of science. We are happy to be one of the first universities in the world outside of Germany in which a joint research center is being established with the Max Planck Society, and look forward to further cooperation in the future.”

Related Links:

Max Planck Institute of Neurobiology
Hebrew University of Jerusalem



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.